Integrated Diagnostics Holdings plc (IDGXF) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Integrated Diagnostics Holdings plc $1.33, price $0.53, upside +151.2%, quality 77 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Integrated Diagnostics Holdings plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.2615 – $1.35 · fair‑value band $0.7700 – $2.39 · the $0.5295 price screens below the $1.33 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Integrated Diagnostics Holdings in your weekly email
Every Wednesday you see whether Integrated Diagnostics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics.
Show more
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.
Stock analysis
Integrated Diagnostics Holdings plc (IDGXF) currently trades at $0.5295, while our model-based Fair Value estimate is $1.33, implying the stock looks roughly 60.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $1.67 per share, and 22 of the 24 models we run sit above the $0.5295 price.
Bear case: the Economic Profit group reads lowest at $0.4580, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.7700 (bear) to $2.39 (bull), the price of $0.5295 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Integrated Diagnostics Holdings plc reported revenue of 7.9B EGP in FY2025 versus 5.2B EGP in FY2021, a compound +10.7%/yr. Reported net income was 1.3B EGP in FY2025, compounding −2.8%/yr from FY2021.
Key figures
Market cap $335M · P/E ratio 10.6 · P/S ratio 1.70 · EPS (TTM) $0.0500 · Net margin 16.1% · Return on equity 34.1% · Return on assets (EBIT) 21.3% · Revenue (TTM) 6.8B EGP.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 151%, IDGXF screens cheaper than that median.
Fair Value models
Bear $0.7700Fair Value $1.33Bull $2.39
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0367 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+37.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
Start year 2020 (pandemic). Over 10 years: +22.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in EGP (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in EGP: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17% vs 25%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 27%
2025 sits 141% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in EGP, Egypt: IMF forecast 8.8% a year to 2030, 16.2% from 2016 to 2025) that is about −10.2% a year for the price.
Compare Integrated Diagnostics Holdings plc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+151% · Top 25%
Profitability
Return on equity (TTM)34% · Top 25%
Return on assets17% · Top 25%
Net margin (TTM)17% · Top 25%
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth31% · Top 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Integrated Diagnostics Holdings plc (IDGXF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.33 versus a price of $0.5295, about +151% upside (undervalued).
What is the fair value of IDGXF?
Our model-based fair value for Integrated Diagnostics Holdings plc is $1.33 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.5295.
What is the quality score of IDGXF?
Integrated Diagnostics Holdings plc has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integrated Diagnostics Holdings plc (IDGXF)?
Our model-based price target is the fair value of $1.33 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $0.7700, optimistic scenario $2.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Integrated Diagnostics Holdings plc stock forecast for 2026?
Our models put fair value at $1.33, about +151% upside versus a price of $0.5295 (undervalued). Cautious scenario $0.7700, optimistic scenario $2.39. The calculation is refreshed regularly with new filings.
What is the revenue of Integrated Diagnostics Holdings plc (IDGXF)?
Integrated Diagnostics Holdings plc reported trailing-twelve-month revenue of about 6.8B EGP (latest available figure, as of Sep 23, 2026).
What growth is priced into Integrated Diagnostics Holdings plc (IDGXF)?
For today's price to be fair in a discounted-cash-flow model, Integrated Diagnostics Holdings plc would have to grow free cash flow by -2.3 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of IDGXF use?
Our models discount Integrated Diagnostics Holdings plc at 9.8 %: a base by market capitalisation (small), damped by beta 0.38, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Integrated Diagnostics Holdings plc that is -2.3 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Integrated Diagnostics Holdings plc (IDGXF) delivered so far?
Over the past 5 years revenue at Integrated Diagnostics Holdings plc grew +24.2 % a year. The price currently implies -2.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Integrated Diagnostics Holdings plc (IDGXF) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Integrated Diagnostics Holdings plc (-2.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Integrated Diagnostics Holdings plc (IDGXF)?
The free-cash-flow yield on the price is 8.69 %: that much free cash flow Integrated Diagnostics Holdings plc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Integrated Diagnostics Holdings plc (IDGXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integrated Diagnostics Holdings plc it is $1.33 per share (as of Sep 23, 2026), against a price of $0.5295. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Integrated Diagnostics Holdings plc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IDGXF trades below its calculated fair value: price $0.5295, fair value $1.33, a gap of about +151% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDGXF?
No. The price is what the market pays today ($0.5295); the fair value is what the company's own numbers justify ($1.33). For Integrated Diagnostics Holdings plc the two are $0.8005 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integrated Diagnostics Holdings plc worth?
The market values Integrated Diagnostics Holdings plc at about $335M (market capitalisation, as of Sep 23, 2026). Per share that is $0.5295; our models calculate a fair value of $1.33 per share.
What do the bullish and bearish scenarios say about IDGXF?
Our models span a range for Integrated Diagnostics Holdings plc: cautious scenario $0.7700, base $1.33, optimistic $2.39 per share (as of Sep 23, 2026, price $0.5295). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IDGXF?
Integrated Diagnostics Holdings plc trades at a price-to-earnings ratio of 10.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.33 is built from several models across several years. Other multiples: P/B 5.1, P/S 2.6, EV/EBITDA 6.2.
How solid is the balance sheet of Integrated Diagnostics Holdings plc (IDGXF)?
Balance-sheet figures for Integrated Diagnostics Holdings plc (as of Sep 23, 2026): return on equity 34.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is IDGXF from its 52-week high?
Integrated Diagnostics Holdings plc trades at $0.5295, about 23% below its 52-week high of $0.6883 and 20% above the low of $0.4411 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.33 is for.
Which stocks are comparable to Integrated Diagnostics Holdings plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integrated Diagnostics Holdings plc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.5295, calculated fair value $1.33 (+151%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDGXF calculated?
We run Integrated Diagnostics Holdings plc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.33, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Integrated Diagnostics Holdings plc currently trades 151 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integrated Diagnostics Holdings plc (IDGXF)?
The closing price on Sep 23, 2026 was $0.5295. Our model-based fair value is $1.33, about +151% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integrated Diagnostics Holdings plc right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($0.7700). The market is more pessimistic than our downside scenario. The model range is unusually wide ($0.7700 to $2.39). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Integrated Diagnostics Holdings plc (IDGXF) come from?
Earnings per share at Integrated Diagnostics Holdings plc grew +20.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +21.8 %, EBIT margin −3.6 %, tax rate +0.7 %, residual (interest, one-offs) +2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Integrated Diagnostics Holdings plc
How large is the market capitalisation of Integrated Diagnostics Holdings plc (IDGXF)?
The market capitalisation of Integrated Diagnostics Holdings plc is $335M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integrated Diagnostics Holdings plc (IDGXF)?
The price-to-sales ratio of Integrated Diagnostics Holdings plc is 1.70 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integrated Diagnostics Holdings plc (IDGXF)?
Earnings per share at Integrated Diagnostics Holdings plc are $0.0500 (price ÷ EPS = P/E 10.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Integrated Diagnostics Holdings plc (IDGXF)?
The net margin of Integrated Diagnostics Holdings plc is 16.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integrated Diagnostics Holdings plc (IDGXF)?
The return on equity (ROE) of Integrated Diagnostics Holdings plc is 34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integrated Diagnostics Holdings plc (IDGXF)?
On an EBIT basis the return on assets of Integrated Diagnostics Holdings plc is 21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Integrated Diagnostics Holdings plc (IDGXF)?
Revenue at Integrated Diagnostics Holdings plc is growing +31.0% versus a year earlier (3y avg +29.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integrated Diagnostics Holdings plc (IDGXF)?
Earnings per share at Integrated Diagnostics Holdings plc are growing +78.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Integrated Diagnostics Holdings plc (IDGXF) hold?
Integrated Diagnostics Holdings plc holds more cash than debt, 57.6M EGP net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Integrated Diagnostics Holdings plc in the live analysis
One click puts Integrated Diagnostics Holdings plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026